CN101616910A - 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物 - Google Patents

作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物 Download PDF

Info

Publication number
CN101616910A
CN101616910A CN200780041379A CN200780041379A CN101616910A CN 101616910 A CN101616910 A CN 101616910A CN 200780041379 A CN200780041379 A CN 200780041379A CN 200780041379 A CN200780041379 A CN 200780041379A CN 101616910 A CN101616910 A CN 101616910A
Authority
CN
China
Prior art keywords
compound
replaces
optional
group
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN200780041379A
Other languages
English (en)
Chinese (zh)
Inventor
凯文·古基安
查尔斯·朱厄尔
帕特里克·康兰
林盈翔
蒂莫西·钱
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biogen MA Inc
Original Assignee
Biogen Idec MA Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec MA Inc filed Critical Biogen Idec MA Inc
Publication of CN101616910A publication Critical patent/CN101616910A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN200780041379A 2006-09-07 2007-09-07 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物 Pending CN101616910A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84280106P 2006-09-07 2006-09-07
US60/842,801 2006-09-07

Publications (1)

Publication Number Publication Date
CN101616910A true CN101616910A (zh) 2009-12-30

Family

ID=39157878

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200780041379A Pending CN101616910A (zh) 2006-09-07 2007-09-07 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物

Country Status (15)

Country Link
US (1) US8293923B2 (enExample)
EP (1) EP2061786A2 (enExample)
JP (1) JP2010502717A (enExample)
KR (1) KR20090049076A (enExample)
CN (1) CN101616910A (enExample)
AU (1) AU2007292929A1 (enExample)
BR (1) BRPI0716549A2 (enExample)
CA (1) CA2663100A1 (enExample)
IL (1) IL197274A0 (enExample)
MX (1) MX2009002377A (enExample)
NO (1) NO20091326L (enExample)
NZ (1) NZ575410A (enExample)
RU (1) RU2459821C2 (enExample)
WO (1) WO2008030584A2 (enExample)
ZA (1) ZA200901529B (enExample)

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106170486A (zh) * 2013-12-19 2016-11-30 拜耳医药股份有限公司 新吲唑甲酰胺、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN106222183A (zh) * 2016-07-25 2016-12-14 南通大学 靶向人irak1基因的小干扰rna及其应用
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
CN108864151A (zh) * 2010-11-19 2018-11-23 利亘制药公司 杂环胺及其用途
CN110305109A (zh) * 2014-11-26 2019-10-08 拜耳医药股份有限公司 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN114585609A (zh) * 2019-06-27 2022-06-03 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途
CN115710253A (zh) * 2021-08-23 2023-02-24 上海交通大学 一类含有氨基苯并咪唑类衍生物及其制备和用途

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2243481A1 (en) * 2009-04-24 2010-10-27 PamGene B.V. Irak kinase family as novel drug target for Alzheimer
US9353087B2 (en) * 2012-06-08 2016-05-31 Biogen Ma Inc. Inhibitors of Bruton's tyrosine kinase
US9598440B2 (en) 2012-10-08 2017-03-21 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
US9586948B2 (en) 2012-10-08 2017-03-07 Merck Sharp & Dohme Corp. Inhibitors of IRAK4 activity
EP2746259A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
EP2746260A1 (en) 2012-12-21 2014-06-25 Basf Se Substituted [1,2,4]triazole and imidazole compounds
RS56269B1 (sr) * 2013-02-07 2017-11-30 Merck Patent Gmbh Makrociklični piridazinon derivati
US9567320B2 (en) * 2013-02-07 2017-02-14 Merck Patent Gmbh Pyridazinone-amides derivatives
US20160166576A1 (en) 2013-07-11 2016-06-16 Merck Sharp & Dohme Corp. Substituted amidopyrazole inhibitors of interleukin receptor-associated kinases (irak-4)
HRP20181795T1 (hr) * 2014-01-13 2019-01-25 Aurigene Discovery Technologies Limited Biciklički heterociklilni derivati kao inhibitori irak4
EP3157521A4 (en) * 2014-06-20 2018-02-14 Aurigene Discovery Technologies Limited Substituted indazole compounds as irak4 inhibitors
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
US10807983B2 (en) 2015-03-16 2020-10-20 Ligand Pharmaceuticals, Inc. Imidazo-fused heterocycles and uses thereof
UY36660A (es) 2015-04-30 2016-11-30 Bayer Pharma AG Combinaciones de inhibidores de irak4
EP3195865A1 (de) 2016-01-25 2017-07-26 Bayer Pharma Aktiengesellschaft Kombinationen von irak4 inhibitoren und btk inhibitoren
US10435396B2 (en) 2016-03-03 2019-10-08 Bayer Pharma Aktiegesellschaft 2-substituted indazoles, methods for producing same, pharmaceutical preparations that contain same, and use of same to produce drugs
EP3219329A1 (en) 2016-03-17 2017-09-20 Bayer Pharma Aktiengesellschaft Combinations of copanlisib
PL3448848T3 (pl) 2016-04-29 2024-03-11 Bayer Pharma Aktiengesellschaft Postać polimorficzna N-{6-(2-hydroksypropan-2-ylo)-2-[2-(metylosulfonylo)etylo]-2H-indazol-5-ilo}-6-(trifluorometylo)pirydyno-2-karboksyamidu
PT3448849T (pt) 2016-04-29 2020-06-30 Bayer Pharma AG Síntese de indazóis
AU2017272505B9 (en) 2016-06-01 2021-10-28 Bayer Pharma Aktiengesellschaft Substituted indazoles useful for treatment and prevention of allergic and/or inflammatory diseases in animals
JOP20180011A1 (ar) 2017-02-16 2019-01-30 Gilead Sciences Inc مشتقات بيرولو [1، 2-b]بيريدازين
US11419875B2 (en) 2017-03-31 2022-08-23 Aurigene Discovery Technologies Limited Compounds and compositions for treating hematological disorders
MX2020004155A (es) 2017-10-19 2020-08-03 Bayer Animal Health Gmbh Uso de pirrolidonas heteroaromaticas fusionadas para el tratamiento y prevencion de enfermedades en animales.
EP3704108B1 (en) 2017-10-31 2024-04-24 Curis, Inc. Irak4 inhibitor in combination with a bcl-2 inhibitor for use in treating cancer
WO2019111218A1 (en) 2017-12-08 2019-06-13 Cadila Healthcare Limited Novel heterocyclic compounds as irak4 inhibitors
TWI842978B (zh) 2018-07-13 2024-05-21 美商基利科學股份有限公司 衍生物
WO2020097398A1 (en) 2018-11-07 2020-05-14 Dana-Farber Cancer Institute, Inc. Benzothiazole derivatives and 7-aza-benzothiazole derivatives as janus kinase 2 inhibitors and uses thereof
CA3181537A1 (en) 2020-05-06 2021-11-11 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
WO2022140527A1 (en) 2020-12-23 2022-06-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
KR20240004476A (ko) 2021-04-08 2024-01-11 쿠리스 인코퍼레이션 암 치료를 위한 병용 요법
CA3234638A1 (en) 2021-11-09 2023-05-19 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as jak2 inhibitors
TW202325289A (zh) 2021-11-09 2023-07-01 美商雅捷可斯治療公司 Ｊａｋ２抑制劑之形式及組合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8716111D0 (en) * 1987-07-08 1987-08-12 Unilever Plc Edible plastic dispersion
IL129337A0 (en) * 1996-11-15 2000-02-17 Darwin Discovery Ltd Bicyclic aryl carboxamides and their therapeutic use
JP2001518094A (ja) * 1997-03-31 2001-10-09 デュポン ファーマシューティカルズ カンパニー Ｈｉｖプロテアーゼ阻害剤として有用なインダゾール−環式尿素
SI1194425T1 (sl) * 1999-06-23 2005-12-31 Sanofi Aventis Deutschland Substituirani benzimidazoli
ATE511840T1 (de) * 2001-10-09 2011-06-15 Amgen Inc Imidazolderivate als entzündungshemmende mittel
JP4628678B2 (ja) 2002-03-29 2011-02-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド 置換ベンズアゾールおよびＲａｆキナーゼ阻害剤としてのそれらの使用

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108864151A (zh) * 2010-11-19 2018-11-23 利亘制药公司 杂环胺及其用途
CN106170486A (zh) * 2013-12-19 2016-11-30 拜耳医药股份有限公司 新吲唑甲酰胺、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN106170486B (zh) * 2013-12-19 2019-01-15 拜耳医药股份有限公司 新吲唑甲酰胺、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN106458982A (zh) * 2014-01-10 2017-02-22 奥列基因发现技术有限公司 作为irak4抑制剂的吲唑化合物
CN110305109A (zh) * 2014-11-26 2019-10-08 拜耳医药股份有限公司 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN110305109B (zh) * 2014-11-26 2022-04-08 拜耳医药股份有限公司 新型取代的吲唑、其制备方法、包含其的药物制剂及其用于制备药物的用途
CN106222183A (zh) * 2016-07-25 2016-12-14 南通大学 靶向人irak1基因的小干扰rna及其应用
CN106222183B (zh) * 2016-07-25 2019-11-08 南通大学 靶向人irak1基因的小干扰rna及其应用
CN114585609A (zh) * 2019-06-27 2022-06-03 比奥根Ma公司 2h-吲唑衍生物及其在疾病治疗中的用途
CN115710253A (zh) * 2021-08-23 2023-02-24 上海交通大学 一类含有氨基苯并咪唑类衍生物及其制备和用途
CN115710253B (zh) * 2021-08-23 2024-07-02 上海交通大学 一类含有氨基苯并咪唑类衍生物及其制备和用途

Also Published As

Publication number Publication date
CA2663100A1 (en) 2008-03-13
EP2061786A2 (en) 2009-05-27
BRPI0716549A2 (pt) 2013-09-24
RU2459821C2 (ru) 2012-08-27
US8293923B2 (en) 2012-10-23
ZA200901529B (en) 2009-11-25
NO20091326L (no) 2009-04-01
JP2010502717A (ja) 2010-01-28
WO2008030584A2 (en) 2008-03-13
MX2009002377A (es) 2009-03-13
IL197274A0 (en) 2009-12-24
AU2007292929A1 (en) 2008-03-13
RU2009112598A (ru) 2010-10-20
NZ575410A (en) 2012-03-30
KR20090049076A (ko) 2009-05-15
US20110152260A1 (en) 2011-06-23
WO2008030584A3 (en) 2008-07-17

Similar Documents

Publication Publication Date Title
CN101616910A (zh) 作为白细胞介素-1受体相关激酶调节剂的吲唑衍生物
EP4139286B1 (en) Substituted aminothiazoles as dgkzeta inhibitors for immune activation
DK2766359T5 (en) Heterocyclic compounds and their use as modulators of type III receptor tyrosine kinases
JP2005526831A (ja) 医薬化合物
KR20190012167A (ko) 이소퀴놀린-3-일 카르복스아마이드 및 이의 제제와 용도
CN115605463B (zh) 用于治疗疾病的受体相互作用蛋白激酶i的抑制剂
CN102015717A (zh) 趋化因子受体调节剂
US7268151B2 (en) Di-aryl substituted triazole modulators of metabotropic glutamate receptor-5
EP2063962A2 (en) Irak modulators for treating an inflammatory condition, cell proliferative disorder, immune disorder
AU2003213783A1 (en) Di-aryl substituted tetrazole modulators of metabotropic glutamate receptor-5
CN102918046A (zh) Jnk的抑制剂
ZA200409346B (en) Kinase inhibitors.
WO2025111513A1 (en) Compounds useful in the modulation of klhdc1 and klhdc2 activity
HK1200814B (en) Heterocyclic compounds and use thereof as modulators of type iii receptor tyrosine kinases
HK1164853B (en) Pyridazinone derivatives
HK1164853A1 (en) Pyridazinone derivatives
HK1159989B (en) Bicyclic triazole derivatives for treating tumors
HK1159989A1 (en) Bicyclic triazole derivatives for treating tumors

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20091230